FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2599603205> ?p ?o ?g. }

• W2599603205 endingPage "36627" @default.
• W2599603205 startingPage "36614" @default.
• W2599603205 abstract "// Weirong Kang 1 , Darren Svirskis 1 , Vijayalekshmi Sarojini 2 , Ailsa L. McGregor 1 , Joseph Bevitt 3 and Zimei Wu 1 1 School of Pharmacy, University of Auckland, Auckland 1142, New Zealand 2 School of Chemical Sciences, University of Auckland, Auckland 1142, New Zealand 3 Australian Centre for Neutron Scattering, Australian Nuclear Science and Technology Organization, Sydney 2232, Australia Correspondence to: Zimei Wu, email: z.wu@auckland.ac.nz Keywords: boron neutron capture therapy (BNCT), dual-targeting drug delivery, glioblastomas, Integrin αv and β3, cyclic RGD peptides Received: November 09, 2016      Accepted: March 01, 2017      Published: March 28, 2017 ABSTRACT The efficacy of boron neutron capture therapy depends on the selective delivery of 10 B to the target. Integrins αvβ3 are transmembrane receptors over-expressed in both glioblastoma cells and its neovasculature. In this study, a novel approach to dual-target glioblastoma vasculature and tumor cells was investigated. Liposomes (124 nm) were conjugated with a αvβ3 ligand, cyclic arginine-glycine-aspartic acid-tyrosine-cysteine peptide (c(RGDyC)-LP) (1% molar ratio) through thiol-maleimide coupling. Expression of αvβ3 in glioblastoma cells (U87) and human umbilical vein endothelial cells (HUVEC), representing tumor angiogenesis, was determined using Western Blotting with other cells as references. The results showed that both U87 and HUVEC had stronger expression of αvβ3 than other cell types, and the degree of cellular uptake of c(RGDyC)-LP correlated with the αvβ3-expression levels of the cells. In contrast, control liposomes without c(RGDyC) showed little cellular uptake, regardless of cell type. In an in vitro boron neutron capture therapy study, the c(RGDyC)-LP containing sodium borocaptate generated more rapid and significant lethal effects to both U87 and HUVEC than the control liposomes and drug solution. Interestingly, neutron irradiated U87 and HUVEC showed different types of subsequent cell death. In conclusion, this study has demonstrated the potential of a new dual-targeting strategy using c(RGDyC)-LP to improve boron neutron capture therapy for glioblastoma." @default.
• W2599603205 created "2017-04-07" @default.
• W2599603205 creator A5019081552 @default.
• W2599603205 creator A5046913723 @default.
• W2599603205 creator A5054049125 @default.
• W2599603205 creator A5062344713 @default.
• W2599603205 creator A5068480189 @default.
• W2599603205 creator A5088941419 @default.
• W2599603205 date "2017-03-28" @default.
• W2599603205 modified "2023-10-09" @default.
• W2599603205 title "Cyclic-RGDyC functionalized liposomes for dual-targeting of tumor vasculature and cancer cells in glioblastoma: An <i>in vitro</i> boron neutron capture therapy study" @default.
• W2599603205 cites W107366461 @default.
• W2599603205 cites W1492513032 @default.
• W2599603205 cites W1553763991 @default.
• W2599603205 cites W1898103072 @default.
• W2599603205 cites W1966781575 @default.
• W2599603205 cites W1967908989 @default.
• W2599603205 cites W1968647565 @default.
• W2599603205 cites W1970094203 @default.
• W2599603205 cites W1972314686 @default.
• W2599603205 cites W1988567685 @default.
• W2599603205 cites W1988742771 @default.
• W2599603205 cites W1997246078 @default.
• W2599603205 cites W1997449859 @default.
• W2599603205 cites W2002523933 @default.
• W2599603205 cites W2003043269 @default.
• W2599603205 cites W2009470459 @default.
• W2599603205 cites W2010065190 @default.
• W2599603205 cites W2018781735 @default.
• W2599603205 cites W2019228746 @default.
• W2599603205 cites W2019428332 @default.
• W2599603205 cites W2024697400 @default.
• W2599603205 cites W2028750783 @default.
• W2599603205 cites W2030613469 @default.
• W2599603205 cites W2031033113 @default.
• W2599603205 cites W2043963298 @default.
• W2599603205 cites W2044966365 @default.
• W2599603205 cites W2049173543 @default.
• W2599603205 cites W2052110007 @default.
• W2599603205 cites W2058023804 @default.
• W2599603205 cites W2058426014 @default.
• W2599603205 cites W2062132947 @default.
• W2599603205 cites W2063540965 @default.
• W2599603205 cites W2063717817 @default.
• W2599603205 cites W2066336297 @default.
• W2599603205 cites W2071966143 @default.
• W2599603205 cites W2072889522 @default.
• W2599603205 cites W2077200168 @default.
• W2599603205 cites W2079925200 @default.
• W2599603205 cites W2084170466 @default.
• W2599603205 cites W2086415594 @default.
• W2599603205 cites W2094377234 @default.
• W2599603205 cites W2099606720 @default.
• W2599603205 cites W2113095686 @default.
• W2599603205 cites W2114286636 @default.
• W2599603205 cites W2117657012 @default.
• W2599603205 cites W2118954030 @default.
• W2599603205 cites W2121357123 @default.
• W2599603205 cites W2135378138 @default.
• W2599603205 cites W2139244140 @default.
• W2599603205 cites W2145030327 @default.
• W2599603205 cites W2147000598 @default.
• W2599603205 cites W2148264571 @default.
• W2599603205 cites W2160433172 @default.
• W2599603205 cites W2171086905 @default.
• W2599603205 cites W2178785249 @default.
• W2599603205 cites W2194508438 @default.
• W2599603205 cites W2221229051 @default.
• W2599603205 cites W2263829954 @default.
• W2599603205 cites W4244591174 @default.
• W2599603205 cites W54801374 @default.
• W2599603205 doi "https://doi.org/10.18632/oncotarget.16625" @default.
• W2599603205 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5482681" @default.
• W2599603205 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28402271" @default.
• W2599603205 hasPublicationYear "2017" @default.
• W2599603205 type Work @default.
• W2599603205 sameAs 2599603205 @default.
• W2599603205 citedByCount "42" @default.
• W2599603205 countsByYear W25996032052017 @default.
• W2599603205 countsByYear W25996032052018 @default.
• W2599603205 countsByYear W25996032052019 @default.
• W2599603205 countsByYear W25996032052020 @default.
• W2599603205 countsByYear W25996032052021 @default.
• W2599603205 countsByYear W25996032052022 @default.
• W2599603205 countsByYear W25996032052023 @default.
• W2599603205 crossrefType "journal-article" @default.
• W2599603205 hasAuthorship W2599603205A5019081552 @default.
• W2599603205 hasAuthorship W2599603205A5046913723 @default.
• W2599603205 hasAuthorship W2599603205A5054049125 @default.
• W2599603205 hasAuthorship W2599603205A5062344713 @default.
• W2599603205 hasAuthorship W2599603205A5068480189 @default.
• W2599603205 hasAuthorship W2599603205A5088941419 @default.
• W2599603205 hasBestOaLocation W25996032051 @default.
• W2599603205 hasConcept C153911025 @default.
• W2599603205 hasConcept C185592680 @default.
• W2599603205 hasConcept C202751555 @default.
• W2599603205 hasConcept C502942594 @default.
• W2599603205 hasConcept C55493867 @default.

• next